Interpace Biosciences (OTCQX: IDXG) is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
Interpace Diagnostics is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management.
Interpace Pharma Solutions provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries and advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.
|
|
|
51-200 employees
View all Interpace Biosciences employees
|
|
Biotechnology
|
|
300 Interpace Pkwy, Parsippany, New Jersey 07054, US
|
|
Molecular Diagnostics And Personalized Medicine
|
Tom Burnell is the CEO of Interpace Biosciences. To contact Tom Burnell email at [email protected]. Or you may call +1.4026134184
The decision makers in Interpace Biosciences are Boaz Kurtis, Christopher Mccarthy, Ginette Halvorsen, etc. Click to Find Interpace Biosciences decision makers emails.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.